Today, validating new therapeutic strategies for RAS-dependent diseases presents significant challenges, including high genetic heterogeneity, difficult statistical predictability, high costs, and low molecular screening. Our dedication is to tackle these challenges, aiming to enhance the lives of patients affected by specific tumors.